Manila Times Business
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting procedures MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD” or the "Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid a
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
2h ago
Manganese X Energy to Present at the June 16 Energy & Precious Metals Virtual Investor Summit
2h ago
Energy & Precious Metals Virtual Investor Summit Agenda Announced for June 16th
2h ago
WatchMatic Highlights Market Trends Influencing Luxury Watch Investment Strategies
2h ago